ClinicalTrials.gg
CompletedNCT04166942Updated Jul 18, 2022

KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

A Phase 1 interventional study of KD025 in Hepatic Impairment, sponsored by Kadmon, a Sanofi Company. Completed at 5 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-18.

Sponsored by Kadmon, a Sanofi Company (part of Sanofi) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a study to characterize the pharmacokinetics, safety and tolerability of KD025 and KD025 metabolites in subjects with mild, moderate or severe hepatic impairment compared to healthy subjects with normal hepatic function.

Read the detailed description

The primary objective of the study is:

  • To assess the pharmacokinetics (PK) of KD025 following a single oral dose of KD025 in subjects with mild, moderate, or severe hepatic impairment compared to healthy subjects with normal hepatic function.

The secondary objectives of the study are:

  • To evaluate the safety and tolerability of a single oral dose of KD025 in subjects with mild, moderate, or severe hepatic impairment, and in healthy subjects with normal hepatic function.
  • To assess the PK of the KD025 metabolites following a single oral dose of KD025 in subjects with mild, moderate, or severe hepatic impairment compared to healthy subjects with normal hepatic function.
02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Kadmon, a Sanofi Company is the lead sponsor of 14 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

First submitted before Kadmon Corporation, LLC became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For All Subjects:

Subjects must satisfy all of the following criteria at the Screening visit, unless otherwise stated:

  1. Males or females, of any race, between 18 and 75 years of age, inclusive.
  2. between 18.0 and 38.0 kg/m\^2, inclusive.
  3. Females of non- defined as permanently sterile (ie, due to hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or (defined as females at least 45 years of age with at least 12 months post-cessation of menses without an alternative medical cause, even with a follicle-stimulating hormone level ≤40 mIU/mL, unless on hormone replacement therapy).
  4. Males will agree to use
  5. Male subjects must not donate sperm from Check-in (Day -1) until 90 days after the Follow-up visit.
  6. Able to comprehend and willing to sign an form and to abide by the study restrictions.

    For Subjects with Normal Hepatic Function Only:

  7. In good health, determined by no findings from medical history, PE, 12-lead , vital sign measurements, and clinical laboratory evaluations at Screening and Check-in (Day -1), as assessed by the Investigator (or designee).
  8. Matched to subjects with mild, moderate, or severe hepatic impairment in sex, age (±10 years), and body mass index (±20%).

    For Subjects with Hepatic Impairment Only:

  9. Documented chronic stable liver disease ( Class A [mild], B [moderate], or C [severe] at Screening); diagnosis of hepatic impairment due to parenchymal liver disease. If the Child-Pugh Class of a subject differs between Screening and Check-in, the Child-Pugh Class documented at Screening will be utilized for enrollment. This will exclude biliary liver cirrhosis or other causes of hepatic impairment unrelated to parenchymal disorder.:

    • 'Documented' is defined by at least 1 of the following: medical history, PE, hepatic ultrasound, computed axial tomography scan, magnetic resonance imaging, and/or liver .
    • 'Chronic' is defined as >6 months.
    • 'Stable' is defined as no clinically significant change in disease status within the last 3 months (90 days), as documented by the subject's recent medical history (eg, no worsening of clinical signs of hepatic impairment, or no worsening of total or by more than 50%).
  10. Subjects with mild, moderate, or severe hepatic impairment may have medical findings consistent with their hepatic dysfunction as determined by medical history, PE, 12-lead ECG, vital sign measurements, and clinical laboratory evaluations at Screening and Check-in (Day -1), as assessed by the Investigator (or designee).
  11. Non-hepatic, abnormal clinical laboratory evaluations not clinically relevant, as judged by the Investigator (or designee) and Covance Medical Monitor.
  12. Currently on a stable medication regimen, defined as not starting new drug(s) or changing drug dose(s) within 30 days of administration of study drug (Day 1). Concomitant medications administered within 30 days prior to administration of KD025 (Day 1) must be approved by the Investigator (or designee), Sponsor, and Covance Medical Monitor.
  13. Anemia secondary to hepatic disease will be acceptable, if >9 g/dL and anemia symptoms are not clinically significant as judged by the Investigator (or designee) and Covance Medical Monitor.
  14. count ≥35 × 10\^9 platelets/L.
  15. Subjects with diabetes mellitus may be included, provided the subjects have:

    1. Glycosylated values ≤9.5% at Screening. Subjects with values outside this range may be allowed by the Covance Medical Monitor on a case-by-case basis.
    2. Blood glucose values ≤240 mg/dL at Screening and Check-in (Day -1) while on subjects' normal diabetes medication.

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from the study if they satisfy any of the following criteria at the Screening visit, unless otherwise stated:

For All Subjects:

  1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee).
  2. History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).
  3. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed).
  4. physical examination abnormality, as determined by the Investigator (or designee).
  5. Use or intend to use any drugs known to be moderate or strong inhibitors or inducers of within 14 days prior to dosing, unless deemed acceptable by the Investigator (or designee) in consultation with the Covance Medical Monitor.
  6. Use or intend to use any proton pump inhibitors or H2 antagonists within 14 days prior to dosing, unless deemed acceptable by the Investigator (or designee) in consultation with the Covance Medical Monitor.
  7. Use or intend to use any phytotherapeutic/herbal/plant-derived preparations within 7 days prior to Check-in (Day -1), unless deemed acceptable by the Investigator (or designee).
  8. History of alcoholism or drug/chemical abuse within 2 years prior to Check-in.
  9. Alcohol consumption of >21 units per week for males and >14 units for females. One unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL) wine.
  10. Positive urine drug screen at Screening and/or Check-in (Day -1) that is not otherwise explained by permitted concomitant medication, or positive alcohol test result at Check-in (Day -1). Either a breath or urine alcohol test may be performed in accordance with the standard practice of each CRU.
  11. Positive test.
  12. Participation in a clinical study involving administration of an drug (new chemical entity) in the past 30 days or 5 half-lives (whichever is longer) of the investigational drug, prior to dosing.
  13. Ingestion of poppy seed-, Seville orange-, or grapefruit-containing foods or beverages within 7 days prior to Check-in (Day -1).
  14. Receipt of blood products within 2 months prior to Check-in.
  15. Donation of blood from 3 months prior to Screening, plasma from 2 weeks prior to Screening, or from 6 weeks prior to Screening.
  16. Poor peripheral venous access.
  17. Have previously completed or withdrawn from this study or any other study investigating KD025, and have previously received KD025.
  18. Subjects who, in the opinion of the Investigator (or designee) should not participate in this study.

    For Subjects with Normal Hepatic Function Only:

  19. corrected for heart rate using Fridericia's method (QTcF) >450 ms confirmed by repeat measurement.
  20. Evidence of hepatorenal syndrome and/or estimated range \<90 mL/min, as determined by the Investigator (or designee), calculated using the Cockcroft-Gault equation at Screening and Check-in (Day -1).

    For male subjects: ([1.23 × {140-age} × {weight in kg})])/(serum creatinine in μmol/L) For female subjects: ([1.04 × {140-age} × {weight in kg})])/(serum creatinine in μmol/L)

  21. Ventricular dysfunction or history of risk factors for Torsade de Pointes (e.g., unexplained syncope, known long QT syndrome, heart failure, and cardiomyopathy). Subjects will be excluded if there is a family history of long QT syndrome.
  22. Use or intend to use any prescription medications/products other than hormone replacement therapy, within 14 days prior to dosing, unless deemed acceptable by the Investigator (or designee).
  23. Use or intend to use slow-release medications/products considered to still be active within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
  24. Use or intend to use any nonprescription medications/products including vitamins, and minerals within 7 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
  25. Positive hepatitis panel. Subjects whose results are compatible with prior immunization may be included at the discretion of the Investigator.
  26. Clinically significant abnormal laboratory values (clinical chemistry, hematology, coagulation, and urinalysis), as determined by the Investigator (or designee).
  27. Significant history or clinical manifestation of hepatic disorder, as determined by the Investigator (or designee).
  28. History or presence of liver disease or liver injury as indicated by any clinically significant deviations from normal reference ranges in liver function tests, unless approved by the Investigator (or designee).
  29. Use of tobacco- or nicotine-containing products within 3 months prior to Check-in (Day -1), or positive continine test at Screening or Check-in.

    For Subjects with Hepatic Impairment Only:

  30. QTcF >450 ms (for mild and moderate hepatic impairment) or >470 ms (for severe hepatic impairment), confirmed by repeat measurement
  31. Evidence of hepatorenal syndrome and/or estimated creatinine clearance range \<90 mL/min (for mild and moderate hepatic impairment) or \<60 mL/min (for severe hepatic impairment), as determined by the Investigator (or designee), calculated using the Cockcroft-Gault equation at Screening and Check-in (Day -1) For male subjects: ([1.23 × {140-age} × {weight in kg})])/(serum creatinine in μmol/L) For female subjects: ([1.04 × {140-age} × {weight in kg})])/(serum creatinine in μmol/L)
  32. History of current diagnosis of uncontrolled or significant cardiac disease indicating significant risk of safety for participation in the study including any of the following:

    1. Recent myocardial infarction (within 6 months of Check-in)
    2. Class III or IV congestive heart failure
    3. Unstable angina (within 6 months of Check-in)
    4. Clinically significant (symptomatic) cardiac arrhythmias (e.g., sustained ventricular tachycardia, second or third degree atrioventricular block without a pacemaker
    5. Uncontrolled hypertension
    6. Unexplained syncope
  33. Use or intend to use any prescription medications/products within 14 days of study drug administration, with the exception of stable medication regimen, as approved by the Investigator (or designee), Sponsor, and Covance Medical Monitor; see Inclusion Criterion #12; and prescribed hormone replacement therapy
  34. Values outside the normal range for liver function tests that are not consistent with their hepatic condition, as determined by the Investigator (or designee).
  35. Clinically significant abnormal PE, vital signs, and/or findings that are not consistent with their degree of hepatic dysfunction, as determined by the Investigator (or designee).
  36. Recent history, or the treatment of, esophageal bleeding (within the past 180 days of Screening), unless banded. If banded, it must not have occurred within 90 days of Screening.
  37. Presence of a portosystemic shunt.
  38. Recent history of paracentesis within 30 days prior to Check-in (Day -1).
  39. Current functioning organ transplant or awaiting organ transplant.
  40. Evidence of severe ascites.
  41. Current symptoms or recent history of hepatic encephalopathy (Grade 2 or above) within 3 months prior to Screening.
  42. Smoke more than 10 cigarettes, or use the equivalent tobacco- or nicotine-containing products, per day or inability to refrain from tobacco use 2 hours pre-dose until 4 hours post-dose.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Normal Hepatic Function (Group 1--Control)

    Matched healthy subjects with normal hepatic function

    Drug: KD025

  • Experimental
    Mild Hepatic Impairment (Group 2)

    Subjects with mild hepatic impairment based on Child-Pugh Class A score of 5 or 6

    Drug: KD025

  • Experimental
    Moderate Hepatic Impairment (Group 3)

    Subjects with moderate hepatic impairment based on Child-Pugh Class B score of 7 to 9

    Drug: KD025

  • Experimental
    Severe Hepatic Impairment (Group 4)

    Subjects with severe hepatic impairment based on Child-Pugh Class C score of 10 to 14

    Drug: KD025

Interventions

  • DrugKD025

    Single dose of 200 mg KD025 orally

    Also known as: belumosudil

06

What researchers measure

Primary outcomes

  1. PK: AUC(0-inf)

    Area under the concentration-time curve from time 0 to infinity

    Time frame: Day 1 through Day 3

  2. PK: AUC(0-t)

    Area under the concentration-time curve from time 0 to the last measurable concentration

    Time frame: Day 1 through Day 3

  3. PK: C(max)

    Maximum observed concentration

    Time frame: Day 1 through Day 3

  4. PK: t(max)

    Time of the observed maximum concentration

    Time frame: Day 1 through Day 3

  5. PK: t(1/2)

    Terminal elimination half-life

    Time frame: Day 1 through Day 3

  6. PK: t(last)

    Time of the last measurable concentration

    Time frame: Day 1 through Day 3

  7. PK: CL/F

    Apparent total clearance

    Time frame: Day 1 through Day 3

  8. PK: Vz/F

    Apparent volume of distribution

    Time frame: Day 1 through Day 3

Secondary outcomes

  1. Safety: Incidence and Severity of Adverse Events (AEs)

    Recording of the incidence, severity, relationship to KD025 of AEs and serious adverse events (SAEs)

    Time frame: Screening through Follow-up on Day 10

07

Study locations

5 sites
  • Inland Empire Clinical Trials, LLC-HQ
    Rialto, California 92377, United States
  • Clinical Pharmacology of Miami
    Miami, Florida 33014-3616, United States
  • Advanced Pharma CR, LLC
    Miami, Florida 33147, United States
  • Omega Research Group
    Orlando, Florida 32810, United States
  • The Liver Institute
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: No — Note: Undecided is not acceptable

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Jun 2022, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2019
First posted
Nov 18, 2019
StartActual
Dec 11, 2019
Primary completionActual
Jun 6, 2022
CompletionActual
Jun 6, 2022
Last update
Jul 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04166942
Responsible party
Sponsor
First posted
Nov 18, 2019
Start date
Dec 11, 2019
Primary completion
Jun 6, 2022
Completion
Jun 6, 2022
Last update
Jul 18, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belumosudil

Start the discussion